Pubblicazioni

Autori:

Leo, Francesco; Ortoncelli, Michela; Cascio Ingurgio, ·ruggero; Galli, Benedetta; Grigolato, Laura; Paganini, Claudia; Maurelli, Martina; Veronica Di Brizzi, Eugenia; Lauletta, Giuseppe; Barei, Francesca; Anna Fiasconaro, Chiara; Casale Alloa, Marta; Bruno Guanti, Mario; Gori, Niccolò; Chiricozzi, Andrea; Napolitano, Maddalena; Patruno, Cataldo; Galluzzo, Marco; Rossi, Mariateresa; Balato, Anna; Mariel Ferrucci, Silvia; Valerio Marzano, Angelo; Pezzolo, Elena; Foti, Caterina; Girolomoni, Giampiero; Gargiulo, Luigi; Narcisi, Alessandra; Quaglino, Pietro; Ribero, Simone; Mastorino, Luca

Titolo:

Safety and Efectiveness of Upadacitinib in Patients with Moderate‐to‐Severe Atopic Dermatitis Who Smoke: a 2‐Year Real‐Life Multicenter Study

Anno:

2025

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

ISSN Rivista:

1175-0561

Intervallo pagine:

425-435

Parole chiave:

This study assessed upadacitinib efectiveness and safety in moderate-to-severe AD in a real-life setting, exploring response diferences in relation to smoking habit. The results from our real-world study demonstrate for the frst time the efectiveness and safety profle of upadacitinib in patients who smoke treated with upadaci- tinib for moderate-to-severe AD, showing no signifcant diferences according to smoking status. Upadacitinib emerges as a potentially safe and efec- tive treatment for patients who smoke with moderate- to-severe AD, showing no increase in adverse events in patients without other cardiovascular risk factors. Further and more in-depth long-term studies are required to explore our fndings.

Breve descrizione dei contenuti:

Background Atopic dermatitis (AD) is a chronic infammatory skin condition that signifcantly impairs the quality of life. Recent advancements in systemic therapies, such as Janus kinase (JAK) inhibitors, ofer very efective new treatment options. However, concerns regarding potential adverse events, including cardiovascular and thromboembolic risk, have emerged from clinical studies and call for further real-life investigations. This has highlighted the need to establish specifc risk categories, such as tobacco smokers. Objective This study aims to evaluate the safety and efectiveness of upadacitinib, a JAK1 inhibitor, in patients who smoke with moderate-to-severe AD over a 2-year treatment period, comparing outcomes with patients who do not smoke. Patients and Methods A retrospective multicenter study was conducted across 12 dermatology departments in Italy, includ- ing 375 patients treated with upadacitinib. The presence and intensity of smoking habits as well as efectiveness scores and safety data were collected. Results Patients who smoke accounted for 36.8% of the sample. Two thromboembolic events in patients who do not smoke were recorded in the 2-year (median follow up of 52.6 weeks) observation period. The most common adverse event was acneiform eruption (12.4% of patients after 104 weeks). No signifcant diferences related to safety emerged regarding the presence or absence of a smoking habit. Drug survival was very high with no diferences between the two cohorts (83.5% after 104 weeks for patients who smoke). Conclusions This study suggests that upadacitinib is a safe and efective treatment for moderate-to-severe AD in presence of tobacco smoke, with no signifcant diferences in safety or efectiveness compared with patients who do not smoke.

Id prodotto:

145886

Handle IRIS:

11562/1162651

ultima modifica:

21 maggio 2025

Citazione bibliografica:

Leo, Francesco; Ortoncelli, Michela; Cascio Ingurgio, ·ruggero; Galli, Benedetta; Grigolato, Laura; Paganini, Claudia; Maurelli, Martina; Veronica Di Brizzi, Eugenia; Lauletta, Giuseppe; Barei, Francesca; Anna Fiasconaro, Chiara; Casale Alloa, Marta; Bruno Guanti, Mario; Gori, Niccolò; Chiricozzi, Andrea; Napolitano, Maddalena; Patruno, Cataldo; Galluzzo, Marco; Rossi, Mariateresa; Balato, Anna; Mariel Ferrucci, Silvia; Valerio Marzano, Angelo; Pezzolo, Elena; Foti, Caterina; Girolomoni, Giampiero; Gargiulo, Luigi; Narcisi, Alessandra; Quaglino, Pietro; Ribero, Simone; Mastorino, Luca, Safety and Efectiveness of Upadacitinib in Patients with Moderate‐to‐Severe Atopic Dermatitis Who Smoke: a 2‐Year Real‐Life Multicenter Study «AMERICAN JOURNAL OF CLINICAL DERMATOLOGY» , 2025 , pp. 425-435

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo